American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) . Washington, DC: APA.
Censits, D., Ragland, J., Gur, R., et al (1997) Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophrenia Research, 24, 289–298.
Green, M., Marshall, B., Wirshing, W., et al (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
American Journal of Psychiatry, 154, 799–804.
Green, M., Kern, R., Braff, D., et al (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?
Schizophrenia Bulletin, 26, 119–136.
Hagger, C., Buckley, P., Kenny, J., et al (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 34, 702–712.
Harvey, P. & Keefe, R. (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry, 158, 176–184.
Hoff, A., Faustman, W., Wieneke, M., et al (1996) The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic in-patients. Neuropsychopharmacology, 15, 361–369.
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789–796.
Kay, S. R., Fiszbein, A. & Opler, L. A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.
Keefe, R., Silva, S., Perkins, D., et al (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin, 25, 201–222.
Kern, R., Green, M., Barringer, D., et al (1998) Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological Psychiatry, 44, 726–732.
Kopala, L., Good, K. & Honer, W. (1997) Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Journal of Clinical Psychopharmacology, 17, 308–313.
Lee, M., Thompson, P. & Meltzer, H. (1994) Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry, 55, 82–87.
Lezak, M. (1995) Neuropsychological Assessment (3rd edn). New York: Oxford University Press.
Lussier, I. & Stip, E. (2001) Memory and attention deficits in drug naive patients with schizophrenia. Schizophrenia Research, 48, 45–55.
Marder, S. & Meibach, R. (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825–835.
O'Carroll, R. (1992) Neuropsychology of psychosis. Current Opinion in Psychiatry, 5, 38–44.
Purdon, S., Jones, B., Stip, E., et al (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol. Archives of General Psychiatry, 57, 249–258.
Purdon, S., Malla, A., Labelle, A., et al (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. Journal of Psychiatry and Neuroscience, 26, 137–149.
Sax, K., Strakowski, S. & Keck, P. (1998) Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophrenia Research, 33, 151–155.
Saykin, A., Shtasel, D., Gur, R., et al (1994) Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry, 51, 124–131.
Velligan, D. & Miller, A. (1999) Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. Journal of Clinical Psychiatry, 60, 25–28.